FI4088720T3 - Rimegepantti cgrp-liittyviin häiriöihin - Google Patents
Rimegepantti cgrp-liittyviin häiriöihinInfo
- Publication number
- FI4088720T3 FI4088720T3 FIEP22182756.1T FI22182756T FI4088720T3 FI 4088720 T3 FI4088720 T3 FI 4088720T3 FI 22182756 T FI22182756 T FI 22182756T FI 4088720 T3 FI4088720 T3 FI 4088720T3
- Authority
- FI
- Finland
- Prior art keywords
- pharmaceutical composition
- weight
- rimegepant
- rimegepantt
- cgrp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2063—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862647794P | 2018-03-25 | 2018-03-25 | |
| US201862664761P | 2018-04-30 | 2018-04-30 | |
| US201862774285P | 2018-12-02 | 2018-12-02 | |
| US201862777180P | 2018-12-09 | 2018-12-09 | |
| US201862777625P | 2018-12-10 | 2018-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4088720T3 true FI4088720T3 (fi) | 2025-11-14 |
Family
ID=68060723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22182756.1T FI4088720T3 (fi) | 2018-03-25 | 2019-03-25 | Rimegepantti cgrp-liittyviin häiriöihin |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20210000814A1 (enExample) |
| EP (2) | EP4088720B1 (enExample) |
| JP (2) | JP2021519288A (enExample) |
| KR (1) | KR20200135465A (enExample) |
| CN (1) | CN112153969A (enExample) |
| AU (1) | AU2019242604B2 (enExample) |
| BR (1) | BR112020019396A2 (enExample) |
| CA (1) | CA3094693A1 (enExample) |
| DK (1) | DK4088720T3 (enExample) |
| ES (1) | ES3047659T3 (enExample) |
| FI (1) | FI4088720T3 (enExample) |
| IL (1) | IL277272B1 (enExample) |
| MX (1) | MX2020009856A (enExample) |
| PH (1) | PH12020551425A1 (enExample) |
| PT (1) | PT4088720T (enExample) |
| SG (1) | SG11202009199YA (enExample) |
| WO (1) | WO2019191008A1 (enExample) |
| ZA (2) | ZA202006190B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4088720B1 (en) * | 2018-03-25 | 2025-09-03 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant for cgrp related disorders |
| MX2021008191A (es) * | 2019-01-20 | 2021-08-11 | Biohaven Pharm Holding Co Ltd | Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña. |
| CN114980862A (zh) * | 2019-12-17 | 2022-08-30 | 拜尔哈文制药股份有限公司 | Cgrp抑制剂的鼻内药物组合物 |
| IL295926A (en) * | 2020-02-27 | 2022-10-01 | Biohaven Pharmaceutical Holding Company Ltd Virgin Island Brited Company ׂLtdׁD Brr | Fast-dispersing oral dosage form of Rimgefent |
| KR20220158245A (ko) * | 2020-03-23 | 2022-11-30 | 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. | Cgrp 저해제를 이용한 폐 손상 치료 방법 |
| CA3176432A1 (en) * | 2020-03-29 | 2021-10-07 | Biohaven Pharmaceutical Ireland Dac | Preventative treatment of migraine |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103634A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
| CN116456981A (zh) * | 2020-11-19 | 2023-07-18 | 辉瑞爱尔兰制药公司 | 用于改善的grp抑制剂递送的组合物 |
| CA3202137A1 (en) * | 2020-11-19 | 2022-05-27 | Pfizer Ireland Pharmaceuticals | Compositions for improved delivery of cgrp inhibitors |
| WO2022251752A2 (en) * | 2021-05-25 | 2022-12-01 | Biohaven Pharmaceutical Ireland Dac | Dual treatment of migraine |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| WO2023055758A1 (en) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Preventative treatment of migraine |
| CN114010608A (zh) * | 2021-11-23 | 2022-02-08 | 莱默(北京)药业科技有限公司 | 一种瑞美吉泮冻干口崩片及制备方法 |
| CN115154469A (zh) * | 2022-07-22 | 2022-10-11 | 中国科学院广州生物医药与健康研究院 | 瑞美吉泮或其药学上可接受的盐在制备预防或治疗肥胖的药物中的应用 |
| WO2024062504A1 (en) * | 2022-09-22 | 2024-03-28 | Quisitive Therapeutics | Pharmaceutical composition comprising ubrogepant and administration thereof |
| WO2024211881A1 (en) * | 2023-04-06 | 2024-10-10 | Navinta, Llc | Rimegepant suspension |
| WO2024220974A1 (en) * | 2023-04-21 | 2024-10-24 | Navinta, Llc | Rimegepant fast-dissolving films for oral administration |
| CN117414352A (zh) * | 2023-11-22 | 2024-01-19 | 湖北广济医药科技有限公司 | 一种瑞美吉泮口溶膜剂及其制备方法 |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
| US7704583B2 (en) | 1998-08-14 | 2010-04-27 | R.P.Scherer Technologies, Inc. | Embossed blister pack |
| GB9817793D0 (en) | 1998-08-14 | 1998-10-14 | Scherer Corp R P | The formation of indicia in the base of a blister pack for transference to a body cast therein |
| GB9908014D0 (en) * | 1999-04-08 | 1999-06-02 | Scherer Corp R P | Pharmaceutical compositions |
| CN101232887A (zh) * | 2005-07-29 | 2008-07-30 | 默克公司 | 杂环苯并二氮杂䓬cgrp受体拮抗剂 |
| US8715715B2 (en) * | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| PT3254681T (pt) | 2012-02-27 | 2019-10-01 | Bristol Myers Squibb Co | Sal de n-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9- tetrahidro-5h-ciclohepta[b]piridin-9-il-4-(2-oxo-2,3- dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidina-1- carboxilato |
| US20130225336A1 (en) * | 2012-02-28 | 2013-08-29 | Edward R. Harvey | Method and apparatus for teaching the throwing of a curveball without injury |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| KR20230107902A (ko) * | 2014-02-05 | 2023-07-18 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
| CA2921336A1 (en) * | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| GB201519196D0 (en) * | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
| EP4088720B1 (en) * | 2018-03-25 | 2025-09-03 | Pfizer Ireland Pharmaceuticals Unlimited Company | Rimegepant for cgrp related disorders |
| MX2021008191A (es) * | 2019-01-20 | 2021-08-11 | Biohaven Pharm Holding Co Ltd | Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña. |
-
2019
- 2019-03-25 EP EP22182756.1A patent/EP4088720B1/en active Active
- 2019-03-25 ES ES22182756T patent/ES3047659T3/es active Active
- 2019-03-25 DK DK22182756.1T patent/DK4088720T3/da active
- 2019-03-25 EP EP19776794.0A patent/EP3773572A4/en not_active Withdrawn
- 2019-03-25 SG SG11202009199YA patent/SG11202009199YA/en unknown
- 2019-03-25 WO PCT/US2019/023940 patent/WO2019191008A1/en not_active Ceased
- 2019-03-25 FI FIEP22182756.1T patent/FI4088720T3/fi active
- 2019-03-25 PT PT221827561T patent/PT4088720T/pt unknown
- 2019-03-25 BR BR112020019396-8A patent/BR112020019396A2/pt unknown
- 2019-03-25 MX MX2020009856A patent/MX2020009856A/es unknown
- 2019-03-25 CA CA3094693A patent/CA3094693A1/en active Pending
- 2019-03-25 AU AU2019242604A patent/AU2019242604B2/en active Active
- 2019-03-25 US US16/767,134 patent/US20210000814A1/en not_active Abandoned
- 2019-03-25 IL IL277272A patent/IL277272B1/en unknown
- 2019-03-25 KR KR1020207030358A patent/KR20200135465A/ko not_active Ceased
- 2019-03-25 JP JP2020551496A patent/JP2021519288A/ja not_active Withdrawn
- 2019-03-25 CN CN201980034240.4A patent/CN112153969A/zh active Pending
-
2020
- 2020-05-27 US US16/884,196 patent/US11083724B2/en active Active
- 2020-09-10 PH PH12020551425A patent/PH12020551425A1/en unknown
- 2020-10-06 ZA ZA2020/06190A patent/ZA202006190B/en unknown
-
2021
- 2021-08-08 US US17/396,717 patent/US20220168295A1/en not_active Abandoned
-
2022
- 2022-05-05 ZA ZA2022/04929A patent/ZA202204929B/en unknown
-
2023
- 2023-07-18 JP JP2023116385A patent/JP2023134690A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4088720B1 (en) | 2025-09-03 |
| EP4088720A1 (en) | 2022-11-16 |
| ES3047659T3 (en) | 2025-12-04 |
| ZA202204929B (en) | 2024-10-30 |
| CA3094693A1 (en) | 2019-10-03 |
| AU2019242604A1 (en) | 2020-10-22 |
| PH12020551425A1 (en) | 2021-12-13 |
| IL277272B1 (en) | 2024-09-01 |
| ZA202006190B (en) | 2025-07-30 |
| EP3773572A4 (en) | 2022-01-05 |
| US20210000814A1 (en) | 2021-01-07 |
| US20220168295A1 (en) | 2022-06-02 |
| CN112153969A (zh) | 2020-12-29 |
| JP2023134690A (ja) | 2023-09-27 |
| EP4631944A2 (en) | 2025-10-15 |
| SG11202009199YA (en) | 2020-10-29 |
| US20200383969A1 (en) | 2020-12-10 |
| EP3773572A1 (en) | 2021-02-17 |
| WO2019191008A1 (en) | 2019-10-03 |
| PT4088720T (pt) | 2025-10-15 |
| US11083724B2 (en) | 2021-08-10 |
| BR112020019396A2 (pt) | 2021-01-05 |
| IL277272A (en) | 2020-10-29 |
| DK4088720T3 (da) | 2025-09-29 |
| AU2019242604B2 (en) | 2025-01-02 |
| MX2020009856A (es) | 2020-10-08 |
| KR20200135465A (ko) | 2020-12-02 |
| JP2021519288A (ja) | 2021-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4088720T3 (fi) | Rimegepantti cgrp-liittyviin häiriöihin | |
| MX383665B (es) | Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer. | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| EP4342540A3 (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| JP2018162255A5 (enExample) | ||
| ME02946B (me) | Dimer buprenorfina i njegova upotreba u lecenju gastrointestinalnih poremecaja | |
| WO2017083304A8 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| WO2018060463A3 (en) | Treatment of prostate cancer | |
| JP2017222722A5 (enExample) | ||
| WO2015173701A3 (en) | Pharmaceutical compositions comprising danirixin for treating infectious diseases | |
| FI3666258T3 (fi) | Menetelmä prader-willin oireyhtymän hoitamiseksi | |
| TR201721505A2 (tr) | Li̇nagli̇pti̇n ve metformi̇n i̇çeren kombi̇nasyon | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| JP2018521007A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| JP2017523149A5 (enExample) | ||
| JP2019518736A5 (enExample) | ||
| HRP20230735T1 (hr) | Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| MX385513B (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| AR114006A1 (es) | Combinación farmacéutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor | |
| HRP20230693T1 (hr) | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti | |
| WO2018191634A3 (en) | IMPROVED STABILITY AND BIODAVAILABILITY FORMULATIONS FOR THE ADMINISTRATION OF 4-SUBSTITUTED BENZYLSULFONES (E) -2,6-DIALCOXYSTYRYL |